Gilead Pays Up to $1.9 Billion for Vir’s T-Cell Engagers as Pharma Keeps Buying Oncology Pipelines
The license covers three solid-tumor programs with $90 million upfront. Agilent, Galderma and BlackRock's HPS also closed notable deals in a week with no new IPOs.
Gilead Sciences has licensed three solid-tumor T-cell engagers from Vir Biotechnology in a deal worth up to $1.9 billion. Vir receives $90 million upfront, split between $65 million in cash and $25 million in equity, with the rest tied to milestones.
Why the structure matters
Large pharma has spent 2026 buying optionality rather than companies. Licensing with milestone-heavy terms lets Gilead add oncology shots on goal without the integration cost of an acquisition, while Vir keeps a balance sheet and a stake in the upside.
Other deals from the week
- Agilent Technologies agreed to buy digital-pathology software maker Proscia for $240 million at closing plus up to $30 million in milestones.
- HPS Investment Partners, part of BlackRock, is buying a $2.8 billion stake in the CenterWell senior primary-care joint venture, which runs nearly 150 clinics.
- Galderma agreed to acquire ZO Skin Health from Blackstone for $1.5 billion, on roughly $330 million of trailing net sales.
- AstraZeneca and insitro signed an AI target-discovery collaboration: $40 million upfront, up to about $1.46 billion in milestones.
- Zocdoc made its first acquisition, buying insurance-eligibility startup Sohar Health.
The IPO window
No healthcare IPOs priced during the week. Recursion Pharmaceuticals raised $200 million in a follow-on at $3.25 a share, and First Tracks Biotherapeutics raised about $200 million privately at $32.75. Two SPAC combinations were signed: TriGemX Bio with TCGX Acquisition (about $600 million post-deal equity value) and ArcheNova Biotech with Horizon Space Acquisition I.
Source: Lawrence, Evans & Co. healthcare deals update, Oct. 19, 2026. Reported and written by Paxton-Digital.